ATE296112T1 - Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 - Google Patents

Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12

Info

Publication number
ATE296112T1
ATE296112T1 AT96910650T AT96910650T ATE296112T1 AT E296112 T1 ATE296112 T1 AT E296112T1 AT 96910650 T AT96910650 T AT 96910650T AT 96910650 T AT96910650 T AT 96910650T AT E296112 T1 ATE296112 T1 AT E296112T1
Authority
AT
Austria
Prior art keywords
colitis
substance
animal
antibodies
effectiveness
Prior art date
Application number
AT96910650T
Other languages
English (en)
Inventor
Warren Strober
Ivan Fuss
Markus Neurath
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE296112T1 publication Critical patent/ATE296112T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96910650T 1995-10-25 1996-03-29 Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 ATE296112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/547,979 US5853697A (en) 1995-10-25 1995-10-25 Methods of treating established colitis using antibodies against IL-12
PCT/US1996/004337 WO1997015327A1 (en) 1995-10-25 1996-03-29 Methods of treating established colitis using antibodies against il-12

Publications (1)

Publication Number Publication Date
ATE296112T1 true ATE296112T1 (de) 2005-06-15

Family

ID=24186934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910650T ATE296112T1 (de) 1995-10-25 1996-03-29 Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12

Country Status (10)

Country Link
US (1) US5853697A (de)
EP (1) EP0862461B1 (de)
JP (2) JP4148533B2 (de)
AT (1) ATE296112T1 (de)
AU (1) AU710282B2 (de)
CA (1) CA2235866C (de)
DE (1) DE69634782T2 (de)
ES (1) ES2239329T3 (de)
MX (1) MX9803253A (de)
WO (1) WO1997015327A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
EP1085906B1 (de) * 1998-06-10 2008-08-13 Ophidian Pharmaceuticals, Inc. Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
US7186507B2 (en) * 1999-12-09 2007-03-06 Indiana University Research And Technology Corporation Fluorescent in situ RT-PCR
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
CA2540623A1 (en) * 2003-10-03 2005-04-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischenic mediated central nervous system disorders or injury
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
BRPI0515858A (pt) 2004-12-21 2008-08-12 Centocor Inc anticorpos anti-il-12, epìtopos, composições, métodos e usos
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
EP2261323A1 (de) * 2005-05-31 2010-12-15 The Iams Company Probiotische Katzen-Laktobazillen
EP1885383B1 (de) * 2005-05-31 2016-09-21 IAMS Europe B.V. Katzen probiotisches bifidobacterium
EP1943359B1 (de) * 2005-09-30 2011-06-29 Centocor Ortho Biotech Inc. Zusammensetzungen und verfahren für il13-biomarker
US7776331B1 (en) * 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
PL2124966T3 (pl) 2007-02-01 2016-01-29 Iams Europe B V Sposób zmniejszania reakcji zapalnej i stresu u ssaków za pomocą antymetabolitów glukozy, awokado lub ekstraktów awokado
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
TWI461210B (zh) * 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
KR101781965B1 (ko) 2008-08-14 2017-09-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
MX2012003138A (es) * 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
WO2018112232A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
RS64552B9 (sr) 2018-09-24 2024-02-29 Janssen Biotech Inc Bezbedna i efikasna metoda lečenja ulceroznog kolitisa sa anti-il12/il23 antitelom
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
EP4153220A4 (de) 2020-05-21 2024-09-11 Janssen Biotech, Inc. Verfahren zur behandlung von entzündlicher darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005147A1 (en) * 1988-11-10 1990-05-17 Genetics Institute, Inc. Natural killer stimulatory factor
DK0433827T3 (da) * 1989-12-22 1998-09-28 Hoffmann La Roche Cytotoksisk lumfocytmodningsfaktor
CA2121096A1 (en) * 1993-04-22 1994-10-23 Weng Tao Monoclonal antibodies to bovine cytokines
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JPH0769895A (ja) * 1993-08-27 1995-03-14 Tokyo Tanabe Co Ltd 炎症性腸疾患治療剤
CA2181787A1 (en) * 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases

Also Published As

Publication number Publication date
JP4148533B2 (ja) 2008-09-10
EP0862461B1 (de) 2005-05-25
JP2000502991A (ja) 2000-03-14
EP0862461A1 (de) 1998-09-09
DE69634782T2 (de) 2006-03-23
JP2008169199A (ja) 2008-07-24
DE69634782D1 (de) 2005-06-30
US5853697A (en) 1998-12-29
MX9803253A (es) 1998-09-30
CA2235866A1 (en) 1997-05-01
WO1997015327A1 (en) 1997-05-01
AU5378696A (en) 1997-05-15
CA2235866C (en) 2010-09-28
ES2239329T3 (es) 2005-09-16
AU710282B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
DE69634782D1 (de) Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12
Lawton et al. Some effects of high velocity electrons on wood
WO2005050200A3 (en) Screening assays and methods of tumor treatment
GB8916400D0 (en) Modified igg3
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
DE60330587D1 (de) Screening-Methoden unter Verwendung eines Strukturmodells von FIH
Gabriel et al. Prenatal Exposure to Cocaine Impairs Neuronal Coding of Attention and Discriminative Learning a
DE69702209D1 (de) Stoffe und verfahren in zusammenhang mit der diagnose und therapie der präeclampsie
Pearson et al. Immune depression in trypanosome‐infected mice. III. Suppressor cells
Feuer et al. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates
Luster et al. Alterations of the antibody response following in utero exposure to diethylstilbestrol
Woo et al. Contribution of perineuronal nets to hyperexcitability in pilocarpine‐induced status epilepticus
Watterson et al. Validation of a method to assess ADHD-related impulsivity in animal models
Phipps An experimental study of the behavior of amphipods with respect to light intensity, direction of rays and metabolism
DE69428995D1 (de) Verfahren zur behandlung von neoplastischen erkrankungen unter verwendung von tiazofurin und ribavirin
Sismondo Physical characteristics of the drumming of Meconema thalassinum
DE60027273D1 (de) ASSAY ZUR IDENTIFIKATION VON IgE-ANTIKÖRPER-SUPPRESSOREN
Buzsáki What does the “LTP model of memory” model?
RU95102036A (ru) Способ определения спонтанной двигательной активности крыс
JÍRA SOME ASPECTS OF DIAGNOSIS OF TOXOPLASMOSIS
Michaely et al. Metastatic pancreatic adenocarcinoma in a giraffe
RU97102373A (ru) Способ определения активности патологического процесса у больных рассеянным склерозом
SCHMITERLÖW Depressor and pressor activity of extracts from the aortic wall of cattle.
Torkington Kinetics of deterrence of Gompertzian growth
CA2465327A1 (en) Nonhuman model animal of th2-mediated hyperimmune response

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties